Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: A double-blind study as adjunctive therapy to levodopa

J. M. Rabey*, I. Sagi, M. Huberman, E. Melamed, A. Korczyn, N. Giladi, R. Inzelberg, R. Djaldetti, C. Klein, G. Berecz

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

164 Scopus citations

Fingerprint

Dive into the research topics of 'Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: A double-blind study as adjunctive therapy to levodopa'. Together they form a unique fingerprint.

Keyphrases

Neuroscience

Pharmacology, Toxicology and Pharmaceutical Science